Mystic's key manufacturing technology for drug, biologic delivery systems receives U.S. patent

Mystic Pharmaceuticals, Inc. announces today that it has been granted U.S. Patent No. 7,963,089, "Deep Draw Container Forming Method," for a key manufacturing technology of its VersiDoser™ and VRx2™ drug and biologic delivery systems. Mystic's delivery platforms provide preservative free unit dose packaging and devices for delivery of ophthalmic and intranasal drugs and biologics.

President and CEO of Mystic, Timothy Sullivan states that, "Mystic's delivery platforms are a breakthrough for adherence packaging in the ophthalmic drug delivery market. Unit dose packaging combined with our self administered delivery systems set a new standard for improving patient compliance and treatment outcomes." Mystic's unit dose based delivery system solutions are optimized for route of administration and technical performance requirements specific to the therapeutic application and patient population needs. With optimized VersiDoser™ and VRx2™ delivery systems, patients can precisely and consistently self-administer daily medications to the eye, nose, mouth, ear or topically to the skin.

Mystic's patented VersiDoser™ blister packaging technology is more efficient than traditional aseptic unit dose liquid packaging technologies used by the pharmaceutical industry today. The company's high efficiency packaging and precision delivery systems reduce costs by enabling pharmaceutical manufacturers to package the same number of doses with up to 70% less bulk drug volume. Ergonomic device design simplifies patient use, reduces administration errors thus enhancing the patient experience for improved compliance. Mystic has incorporated its patented manufacturing technology into the VersiDoser™ aseptic blister production system. VersiDoser™ production systems are commercially scalable to production volumes of up to one million doses per day and can be flexibly reconfigured to support a wide range of product requirements.